Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 20

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 20
---
Related, Tax and Other Fees

The following table presents the aggregate fees billed to us by Baker Tilly US, LLP for the fiscal years ended December 31, 2024 and 2023.

|                    |     | Aggregate Amount Billed by 
 Baker Tilly US, LLP        |    2024 |     |   |    2023 |
|:-------------------|:----|:---------------------------|--------:|:----|:--|--------:|
| Audit Fees(1)      |     | $                          | 201,184 |     | $ | 181,834 |
| Audit-Related Fees |     |                            |       — |     |   |       — |
| Tax Fees           |     |                            |       — |     |   |       — |
| All Other Fees     |     |                            |       — |     |   |       — |
| Total              |     | $                          | 201,184 |     | $ | 181,834 |

| (1) | These fees consisted of the audit of our annual consolidated financial statements for 2024 and 2023, review of quarterly condensed consolidated financial statements and other services normally provided in connection with statutory and regulatory filings or engagements. |

Audit Committee Pre-Approval Policies and Procedures

All services rendered by Baker Tilly US, LLP to DiaMedica were permissible under applicable laws and regulations and all services provided to DiaMedica, other than de minimis non-audit services allowed under applicable law, were approved in advance by the Audit Committee. The Audit Committee’s formal written charter requires the Audit Committee to pre-approve all auditing services and permitted non-audit services, including fees for such services, and permits the Audit Committee to establish pre-approval policies and procedures. The Audit Committee has delegated to the Audit Committee Chair the authority to pre-approve certain services up to $25,000.

<div align='center'>16</div>

Board Recommendation

The Board of Directors unanimously recommends that shareholders vote FOR the appointment of Baker Tilly US, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2025 and authorization to the Board of Directors to fix the remuneration of our independent registered public accounting firm.

| The Board of Directors Recommends a Vote FOR Voting Proposal Two |

<div align='center'>17

VOTING PROPOSAL THREE—ADVISORY APPROVAL OF EXECUTIVE COMPENSATION</div>

Background and Proposed Advisory Approval of Our Executive